Supporting agencies: The article was prepared with the financial support of Roche Holding, which did not affect the structure of the study, the data analysis and interpretation, as well as the decision to publish the results.
For citation:
Kolbin А.S., Kurylev А.А., Balykina Yu.Е., Proskurin М.А., Mishinova S.А. Health-economic evaluation of risdiplam (Evrysdi®) in patients with spinal muscular atrophy. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 0;. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.101
Views: 71
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 